The economic value of a quadrivalent versus trivalent influenza vaccine

Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15213, United States. Electronic address: .
Vaccine (Impact Factor: 3.49). 10/2012; 30(52). DOI: 10.1016/j.vaccine.2012.10.025
Source: PubMed

ABSTRACT The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Cost and quality-adjusted life-years (QALYs) gained by quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) in Hong Kong elderly were estimated over 9 seasons.MethodsTIV-unmatched influenza B infection rates with QIV versus TIV were estimated by an epidemiology model. Model parameters included percentages of influenza B lineages in circulation, influenza B-associated hospital admission, age-specific population, vaccine coverage and effectiveness. Incremental cost per QALY gained (ICER) by QIV versus TIV were estimated from Hong Kong¿s societal perspective.ResultsMean reduction in influenza B infection rate was 191.3 (95%CI 45.1-337.5) per 100,000 population aged ¿65 years. Highest cost savings and QALYs gained by QIV occurred in 2007 with high percentage of TIV-unmatched strain (92.9%) for age groups 65¿79 years (USD266,473 and 22.8 QALYs) and ¿80 years (USD483,461 and 27.3 QALYs). ICERs of QIV were below willingness-to-pay for age group 65¿79 years in 6, 5 and 3 years when QIV cost¿+¿USD1¿+¿USD2 and¿+¿USD5 more than TIV, respectively. For age group ¿80 years, ICERs of QIV were below willingness-to-pay in 7 and 5 years when QIV cost¿+¿USD1 and¿+¿USD5, correspondingly.Conclusions Acceptance of QIV to be cost-effective in Hong Kong elderly was subject to QIV unit cost and percentage of circulating TIV-unmatched influenza B lineages.
    BMC Infectious Diseases 11/2014; 14(1):618. DOI:10.1186/s12879-014-0618-9 · 2.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Seniors are particularly vulnerable to complications resulting from influenza infection. Numerous influenza vaccines are available to immunize US seniors, and practitioners must decide which product to use. Options include trivalent and quadrivalent standard-dose inactivated influenza vaccines (IIV3 and IIV4 respectively), as well as a high-dose IIV3 (HD). Our research examines the public health impact, budget impact, and cost-utility of HD versus IIV3 and IIV4 for immunization of US seniors 65 years of age and older.
    Vaccine 11/2014; 33(5). DOI:10.1016/j.vaccine.2014.10.079 · 3.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As the most recent outbreak of Ebola virus disease (EVD) in West Africa continues to grow since its initial recognition as a Public Health Emergency of International Concern, an unanswered question is what is the cost of a case of Ebola? Understanding this cost will help decision makers better understand the impact of each case of EVD, benchmark this against that of other diseases, prioritize which cases may require response, and begin to estimate the cost of Ebola outbreaks. To date, the scientific literature has not characterized this cost per case. Therefore, we developed a mathematical model to estimate the cost of an EVD case from the provider and societal perspectives in the three most affected countries of Guinea, Liberia, and Sierra Leone. Our model estimates the total societal cost of an EVD case with full recovery ranges from $480 to $912, while that of an EVD case not surviving ranges from $5929 to $18 929, varying by age and country. Therefore, as of 10 December 2014, the estimated total societal costs of all reported EVD cases in these three countries range from $82 to potentially over $356 million.
    01/2015; 109(1):2047773214Y0000000169. DOI:10.1179/2047773214Y.0000000169